A survey to understand disease activity measures and viable treatment targets in psoriatic arthritis
 
The GRAPPA and OMERACT (Outcome Measures in Rheumatology Clinical Trials) group are continually striving to optimise the assessment and management of psoriatic arthritis (PsA). As part of these ongoing efforts, the group have issued two independent surveys one to healthcare professionals with an interest in psoriatic arthritis (PsA) and one to patients with PsA. The surveys serve to specifically explore current disease activity measures and improve on these to define a set of measures which better assess disease activity in PsA.  As such, this patient survey has been designed to explore what effective disease control means to patients and how these may work alongside any clinical assessments your rheumatologist may perform in daily practice. To help us gather further insights into effective and meaningful measures for disease activity in PsA the GRAPPA Working Group* would very much appreciate a few minutes of your time to complete this short survey.

Any information you provide us with will be treated as confidential and you will remain anonymous. You have the right to refuse to answer a question or completely withdraw from the survey at any time.

 

*GRAPPA Working Group members:

Dr. L. Coates., NIHR Clinical Lecturer in Rheumatology at the University of Leeds; Dr. Dafna Gladman., Senior Scientist at the Toronto Western Research Institute; Dr. Philip Helliwell., Consultant Rheumatologist/Senior Lecturer, Leeds University; Dr. Philip Mease., MD, clinical professor, University of Washington School of Medicine, Seattle; Prof. P. Nash., Department of Medicine, University of Queensland, Australia; Maarten de Wit, patient research partner

T